beta-Synuclein

01/01/2016 - "Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders."
06/15/2007 - "Beta-synuclein gene variants and Parkinson's disease: a preliminary case-control study."
10/01/2002 - "Development of new treatments for Parkinson's disease in transgenic animal models: a role for beta-synuclein."
07/09/1999 - "No pathogenic mutations in the beta-synuclein gene in Parkinson's disease."
11/15/1998 - "We have observed that the beta-synuclein gene (HGMW-approved symbol, SNCB) is highly expressed in brain including the substantia nigra, the main region of neuronal degeneration in patients with Parkinson disease. "

10/01/2002 - "Such an anti-amyloidogenic property of beta-synuclein might also provide a novel strategy for the treatment of neurodegenerative disorders."
10/25/2001 - "Such an anti-amyloidogenic property of beta-synuclein might also provide a novel strategy for the treatment of neurodegenerative disorders."
11/15/1998 - "We have determined the intron-exon structure of the beta-synuclein gene and established sequencing assays that will facilitate the search for mutations in the beta-synuclein gene in patients with Parkinson disease or other neurodegenerative disorders."
05/10/2004 - "Thus, aberrant accumulation of alpha- and beta-synuclein in degradative organelles are novel features of PS1 -/- neurons, and similar events may promote the formation of alpha-synuclein inclusions associated with neurodegenerative diseases."
01/01/2004 - "Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?"

04/01/2021 - "Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease."
01/01/2020 - "Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease."
01/01/2023 - "Blood beta-synuclein is increased in Alzheimer's disease (AD) but not in frontotemporal lobar degeneration (FTLD) syndromes. "
01/01/2022 - "This exploratory case-control study investigates the synaptic marker beta-synuclein in serum and plasma pTau181 in adults with Down syndrome (DS) with (sDS, n = 14) and without (aDS, n = 47) clinical symptoms of Alzheimer disease (AD) as well as euploid controls (n = 23). "
01/01/2023 - "Recent data support beta-synuclein as a blood biomarker to study synaptic degeneration in Alzheimer's disease (AD). "

12/01/2004 - "An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model."
04/01/2007 - "These results support the contention that in Parkinson's disease and Lewy body dementia, alpha-syn oligomers on the membrane might form pore-like structures, and that the beneficial effects of beta-synuclein might be related to its ability to block the formation of pore-like structures."
01/01/2018 - "Beta-synuclein counteracts aggregation of alpha-synuclein in vitro and in animal models, however it is not clear whether this effect occurs in human Lewy body dementia (LBD) diseases. "
10/01/2006 - "Previous studies have shown that beta-synuclein (beta-syn), the homologue of alpha-syn, inhibited alpha-syn aggregation and stabilized Akt cell survival signaling molecule, suggesting that beta-syn was protective against alpha-syn-related neurodegenerative disorders, such as Parkinson's disease and diffuse Lewy body disease. "

02/28/2011 - "Therefore controlling beta-synuclein expression may control the accumulation of alpha-synuclein and ultimately prevent disease progression. "
11/01/2013 - "In this regard, strategies to counter-regulate the expression of the synucleins by increasing beta-synuclein expression relative to alpha-synuclein may be beneficial in preventing disease progression. "